More than one in three of us will get cancer in our lifetimes. Better prevention, earlier diagnosis, and innovative new treatments mean we have a realistic opportunity to make major improvements in survival.
PreciousMD works on game-changing and disruptive technologies for the detection of the patients who are eligible for receiving targeted therapy. Current approaches are based on invasive and expensive assays on samples taken from the biopsy. This can be significantly improved by advanced computation analysis.
Due to the high mortality rate and massive public cost burden of lung cancer, PreciousMD has focused on this type of cancer at the starting point. Lung cancer is one of the most common and serious types of cancer. Around 49,500 people are diagnosed with the condition every year in the UK. We intend for PreciousMD technology to become a routine part of clinical practice and drug development and substantially improve the way of addressing cancer.
PreciousMD has awarded the “Innovate UK Smart grant” on the 1st of August, 2021. The Smart Grant program funds game-changing and commercially viable R&D innovation that can significantly impact the UK economy. The grant funds the development of an image-based companion diagnostic for the prediction of response to EGFR-inhibiting drugs e.g., Gefitinib (IRESSA), Erlotinib (TARSEVA). Our technology detects eligible lung cancer patients by predicting the EGFR mutational status of their tumor.